Healing
Ara 290
Cognitive
11
Amino acids
Molecular weight
Peptide
Type
ARA 290 (Cibinetide) is a synthetic 11-amino acid peptide derived from the tissue-protective domain of erythropoietin, engineered to selectively activate the innate repair receptor (IRR) without stimulating red blood cell production. It is primarily studied for small fiber neuropathy, sarcoidosis-associated nerve damage, and chronic inflammatory conditions. Researchers and clinicians use it for its demonstrated ability to regenerate small nerve fibers and reduce neuroinflammation in human trials.
Top researched benefits
Overview of Ara 290
ARA 290 binds and activates the innate repair receptor (IRR), a heterodimer of the erythropoietin receptor (EPOR) and the beta-common receptor (CD131/βcR), triggering anti-inflammatory and tissue repair signaling cascades. This activation suppresses NLRP3 inflammasome activity, inhibits NF-κB phosphorylation, reduces pro-inflammatory cytokine production, and stimulates small nerve fiber regrowth at damaged axons.
neuroprotection
- 23% increase in corneal nerve fiber area with sustained pain improvement.
- Nerve regeneration and metabolic improvements in Type 2 diabetes patients.
- Crosses blood-brain barrier for stroke and TBI neuroprotection.
tissue repair
- Improves epithelialization and angiogenesis via VEGF upregulation.
- Reduces infarct size in myocardial infarction models.
- Maintains cardiac function in aging models.
antiinflammatory
- Reduces TNF-α, IL-6, and IL-12 production.
- Reduces colitis severity in animal models.
- Improves graft survival and reduces rejection.
Typical Dose
4mg per injection
Frequency
once daily
Cycle Duration
4 weeks (28 days), subcutaneous self-injection
Storage
Lyophilized: 2–8°C for up to 2 years or −20°C for up to 3 years, protected from light. Reconstituted: 2–8°C for up to 28 days; do not freeze.
Chemical Makeup
Key benefits
Regenerates small nerve fibers in sarcoidosis-associated neuropathy, with a ~23% increase in corneal nerve fiber area demonstrated in Phase 2b trials
Reduces neuropathic pain in small fiber neuropathy by suppressing underlying neuroinflammation rather than acting as a direct analgesic
Improves glycemic control and HDL cholesterol ratios in patients with type 2 diabetes-associated neuropathy
Suppresses NLRP3 inflammasome activation in Schwann cells, reducing peripheral nerve damage after injury
Community interest
This peptide is still gaining traction in the community.
IRR Agonist | Neuropathy & Anti-Inflammatory
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesNoAra 290 Molecular Information
View the scientifc details of Ara 290.
11
Amino Acids
Ara 290
?
?
Position 1
Glu
Glu
Position 2
Gln
Gln
Position 3
Leu
Leu
Position 4
Glu
Glu
Position 5
Arg
Arg
Position 6
Ala
Ala
Position 7
Leu
Leu
Position 8
Asn
Asn
Position 9
Ser
Ser
Position 10
Ser
Ser
Position 11
Molecular Weight
1257.3DaChain Length
11Amino AcidsType
PeptideAra 290 Protocols
Subcutaneous injection is the primary clinically validated route for Ara-290, with Phase 2 trials establishing 4 mg daily SubQ for 28-day courses as the standard for neuropathy and tissue repair. Injection sites are rotated across the abdomen, outer thigh, or upper arm; the peptide does not require proximity to the injury site given its systemic anti-inflammatory mechanism via innate repair receptor activation.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Reduce pain and restore sensation in diabetic small fiber neuropathy over a 28-day course | 4 | 1 day range | SubQ |
| Alleviate small fiber neuropathy symptoms associated with sarcoidosis | 4 | 1 day range | SubQ |
| Reduce systemic inflammation and support tissue repair at a conservative starting dose | 2 | 1 day range | SubQ |
| Improve corneal nerve fiber density as a biomarker of peripheral nerve regeneration | 4 | 1 day range | SubQ |
| Attenuate neuropathic pain via innate repair receptor activation without opioid pathways | 4 | 1 day range | SubQ |
| Assess tolerance and establish individual response before advancing to the full 4 mg clinical dose | 2 | 1 day range | SubQ |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Remove the lyophilized Ara-290 vial from the freezer and allow it to reach room temperature for 10–15 minutes before handling.
- Draw the required volume of bacteriostatic water into an insulin syringe — for a 10 mg vial, draw 2 mL to achieve a 5 mg/mL concentration; for a 16 mg vial, draw 2 mL to achieve an 8 mg/mL concentration.
- Insert the needle through the rubber stopper and inject the bacteriostatic water slowly down the inner wall of the vial — never directly onto the lyophilized powder cake.
- Gently swirl or roll the vial between your palms until the powder fully dissolves — do not shake vigorously, as this degrades the peptide.
- Label the vial with the reconstitution date and refrigerate at 2–8 °C; use within 28 days.
- For a 4 mg dose from a 5 mg/mL solution, draw 0.8 mL (80 insulin syringe units) into a fresh insulin syringe.
- Pinch a fold of skin at the injection site (abdomen, outer thigh, or upper arm) and insert the needle at a 45–90 degree angle.
- Inject slowly and steadily, withdraw the needle, and apply light pressure with clean gauze — do not rub the site.
- Rotate injection sites with each administration to prevent lipohypertrophy.
Ara 290 Cycle
The Ara 290 Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 1-2
- Initial anti-inflammatory effects and mild pain symptom improvement
- Week 2-4
- Progressive nerve regeneration, improved tissue healing markers
- Week 4-6
- Peak therapeutic effects, maximum nerve fiber density improvements
- Month 2-6
- Long-lasting benefits via molecular switch effect
Dosing tools
Ara 290 Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
mg
Enter the total amount of peptide in the vial in milligrams (as stated on the label).
The dose you want to inject per administration, in mcg or mg.
1,000 mcg = 1 mg
1 mL
2 mL
3 mL
5 mL
Custom
Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.
Injection Results
Based on your vial and dilution inputs.
Ara 290
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Ara 290 vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
1mL / 100 units
5 units
0.050 mL
Reference Guide
Dosing Cycle
- Peptide
- Ara 290
- Dosing
- 4mg per injection
- Dosing Frequency
- once daily
- Cycle Duration
- 4 weeks (28 days), subcutaneous self-injection
- Storage
- Lyophilized: 2–8°C for up to 2 years or −20°C for up to 3 years, protected from light. Reconstituted: 2–8°C for up to 28 days; do not freeze.
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of Ara 290 interactions with other common peptides and substances.
Healing
bpc
Longevity
BPC-157
SYNERGISTIC
Complementary tissue repair pathways may enhance wound healing.
Longevity
nad
Metabolic
NAD+
MONITOR
Both affect cellular metabolism; monitor for additive effects.
Weight
GLP-1
Metabolic
GLP-1
COMPATIBLE
No adverse interactions in clinical trials with GLP-1 agonists.
Healing
thymos
Longevity
Thymosin Beta-4
COMPATIBLE
No known interactions; different mechanisms for tissue protection.
Side effects
Monitor: Be careful when combining Ara 290 with NAD+.
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
Stop signs
Severe injection site reactions
Unexpected blood count changes
Allergic reaction signs
Worsening of underlying condition
New neurological symptoms
Any serious adverse events
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What is a peptide dosage calculator?
A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringeunits to draw. This calculator works for single peptide compounds and multi-peptide blends.
How do I calculate peptide dosage from a vial?
To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.
How much Bacteriostatic water should I add to a peptide vial?
Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.
How are peptides different from proteins?
Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.
Ara 290Research References
Ara 290 is a phase 2 compound
Ara 290
Ara 290 is a phase 2 compound
Sarcoidosis Neuropathy Phase 2b Trial
64 patients, 1-8 mg SC daily for 28 days: 23% increase in corneal nerve fiber area at 4 mg dose.
2017
Type 2 Diabetes Neuropathy Phase 2
48 patients, 4 mg SC daily for 28 days: Sustained HbA1c improvement and nerve regeneration.
2015
Diabetic Macular Edema Pilot Study
9 patients, 4 mg SC daily for 12 weeks: Improved quality of life; good safety profile.
2020
Myocardial Infarction Protection Study
Preclinical mouse model, 24 μg/kg IV single dose: Reduced infarct size and improved survival.
2012
Stroke Neuroprotection Research
Rat stroke model, 300 μg/kg IV single dose: Reduced stroke volume; BBB penetration confirmed.
2011
Calculate peptide dosages
Learning how to calculate a peptide dose? Use our beginner-friendly peptide dosage, blend, and accumulation calculators. Enter vial size, reconstitution volume, and target dose to get exact draw volumes instantly. No guesswork, just clear guidance that helps prevent common mistakes.
